CurrentUnitedHealthcarePolicy 2026R6005A

CMS 1500 drug testing reimbursement (presumptive, definitive, specimen validity)

Defines reimbursement rules for drug testing services billed on CMS‑1500 (presumptive, definitive, and specimen validity testing) for UnitedHealthcare Commercial and Individual Exchange plans and providers submitting on CMS‑1500 forms.

Policy Summary

PayerUnitedHealthcare

PolicyCMS 1500 drug testing reimbursement (presumptive, definitive, specimen validity)

Policy CodePolicy 2026R6005A

Change TypeNo material change

Effective Date

Next Review Date

Key ActionDo not bill for more than one presumptive and/or one definitive drug test per patient per date of service; specimen validity testing billed same day will be denied unless clearly separate with modifier and documentation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

one per dayallowed presumptive drug test per patient per date of service

one per dayallowed definitive drug test per patient per date of service

deniedspecimen validity testing when performed same day as presumptive/definitive drug test

applies to all productspolicy applies to UnitedHealthcare Commercial and Individual Exchange

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Reimbursement and Coverage Rules

Reimbursement criteria

Covered with limits and rules as follows:

Reimbursement is subject to the daily limits and rules below as applied to services billed on the CMS-1500 form.

ALL of the following

Presumptive drug testing: UnitedHealthcare allows one presumptive drug test per patient per date of service (each CPT/HCPCS presumptive code represents all drug/Drug Class tests by methodology and is reported once per day).
Presumptive codes include 80305, 80306, 80307, and H0003; each code represents all drug and Drug Class tests performed by the methodology per date of service.

ALL of the following

Definitive (confirmation) drug testing: UnitedHealthcare allows one definitive drug test per patient per date of service (definitive CPTs 80320-80377 are considered non-reimbursable; report HCPCS G0480–G0483 or G0659 as appropriate).
Proprietary Laboratory Analysis (PLA) codes may be reported and are considered under the definitive drug testing guidelines when applicable.

ALL of the following

Specimen validity testing is considered part of presumptive and definitive drug test code descriptions and is an integral quality-control part of collection; it is not separately reimbursable when performed on the same date of service as a presumptive and/or definitive drug test.
UnitedHealthcare will deny specimen validity testing when performed the same date of service as a presumptive and/or definitive drug test by the same or different provider unless a modifier is appended and documentation shows the service was distinctly separate from drug testing.

ALL of the following

Per-day aggregate limit: Only one presumptive and one definitive drug test will be reimbursed per patient per date of service regardless of number of Drug Classes, specimen validations, or number of billing providers.
Modifiers: A modifier may be appropriate to indicate a service commonly used for specimen validity testing was performed distinctly separate from the drug test; documentation must support the separate service and modifier use.

Exceptions and separate services

Other laboratory services (for example, urinalysis for urinary tract infection) may be considered for separate reimbursement if appended with an appropriate modifier and documentation supports the service was not related to specimen validity testing.
Drug testing services that are court-ordered and funded by a county, state or federal agency will be denied as payable to healthcare professionals.

Operational guidance: All services remain subject to other UnitedHealthcare reimbursement policies (e.g., Maximum Frequency Per Day Policy, Laboratory Services Policy, and CCI Editing Policy).

Codes and Per‑Day Limits

Presumptive Drug Testing (Covered CPT/HCPCS)CPTCovered

80305	Drug test, presumptive, any number of drug classes; non-automated instrumented chemistry technique (e.g., immunoassay)
80306	Drug test, presumptive, any number of drug classes; instant result (e.g., point of care)
80307	Drug test, presumptive, any number of drug classes; non-instrumented (e.g., dipstick)
H0003	Alcohol and/or drug services; screening

Definitive Drug Testing (HCPCS — per-day Drug Class counts)HCPCSCovered

G0480	Drug class definitive, definitive drug testing, 1-7 drug classes
G0481	Drug class definitive, 8-14 drug classes
G0482	Drug class definitive, 15-21 drug classes
G0483	Drug class definitive, 22+ drug classes
G0659	Drug testing, definitive, each additional drug class (when applicable)

Definitive Drug Testing (PLA / Proprietary CPT Codes)CPT

0007U	PLA: Definitive testing — panel mapping to drug classes (proprietary)
0011U	PLA: Proprietary definitive drug test (example mapping)
0082U	PLA: Proprietary definitive drug test
0328U	PLA: Proprietary definitive drug test
0517U	PLA: Proprietary definitive drug test series
0518U	PLA: Proprietary definitive drug test
0519U	PLA: Proprietary definitive drug test
0520U	PLA: Proprietary definitive drug test
0587U	PLA: Proprietary definitive drug test

Specimen Validity Testing (Not Separately Reimbursable when same DOS)mixed

81000	Urinalysis, by dipstick or tablet reagent; multiple constituents (mapped series includes 81001, 81002, 81003, 81005)
81001	Urinalysis, by dipstick or tablet reagent; automated
81002	Urinalysis, by dipstick or tablet reagent; non-automated
81003	Urinalysis, by dipstick or tablet reagent; microscopic exam
81005	Urinalysis; with microscopic exam
82542	Assay of urine drug or metabolite (e.g., specific analyte)
82570	Drug assay, qualitative
83516	Toxicology testing, quantitative, major analyte
83518	Toxicology testing, quantitative, other analyte
83519	Toxicology testing, qualitative or quantitative

1–10 of 15

1/2

Per‑day limitOne presumptive drug test and one definitive drug test allowed per patient per date of service across providers.

Billing Guidance and Risk Notices

Billing Rule

Limit billing to one presumptive and one definitive test per patient per day; specimen validity testing not separately payable same day

Do not bill for more than one presumptive and/or one definitive drug test per patient per date of service. Specimen validity testing is included in the presumptive and definitive code descriptions and will be denied when performed on the same date of service as a presumptive and/or definitive drug test by the same or different provider unless the service is distinctly separate, appropriately modified, and supported by documentation.

One presumptive and one definitive drug test allowed per patient per date of service (across providers); UnitedHealthcare will not reimburse more than one presumptive and/or one definitive drug test per day.
Specimen Validity Testing is considered part of presumptive/definitive code descriptions and is not separately reimbursable when performed the same date of service; a modifier may be appropriate only when documentation proves the service was distinctly separate.
Separate laboratory services (e.g., urinalysis for infection) may be considered for reimbursement if appended with an appropriate modifier and records support the service was not for Specimen Validity Testing.

Key Definitions

Drug Class

DefinitionA group of drugs that have the same chemical structure, work in the same way and/or are used for the same purpose.

Use in policyDrug Classes are the basis for counting presumptive and definitive tests per date of service.

Examples referencedPolicy references Drug Class when limiting one presumptive and one definitive drug test per Drug Class per date of service.

Proprietary Laboratory Analysis (PLA) Codes

DefinitionProprietary Laboratory Analysis (PLA) Codes describe proprietary clinical laboratory analysis and can be provided by a single ('sole‑source') laboratory or marketed to multiple providing laboratories; include ADLTs and CDLTs as defined under PAMA.

Coding contextPLA codes are considered under definitive drug testing guidelines in this policy (may be reported as proprietary definitive tests).